FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OLOGICITIES AND EXCITATION	
Washington, D.C. 20549	

OMB APPROVAL 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* SPRINGER TIMOTHY A			2. Issuer Name and Ticker or Trading Symbol Cartesian Therapeutics, Inc. [RNAC]						Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) 36 WOODMAN	(Last) (First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 12/19/2024						Officer (give title below) Other (specify below)				
(Street) CHESTNUT HILL (City)	MA (State)	02467 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			E	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	Amount	(A) or (D)	Price	1	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock			12/19/2024		P		11,303	A	\$17.3858	(1)	8,467,009	D	
Common Stock			12/19/2024		P		10,529	A	\$18.3496	(2)	8,477,538	D	
Common Stock			12/19/2024		P		3,376	A	\$18.928	3)	8,480,914	D	
Common Stock			12/20/2024		P		21,800	A	\$18.9435	(4)	8,502,714	D	
Common Stock			12/23/2024		P		5,181	A	\$18.9996	(5)	8,507,895	D	
Common Stock											330,695	I	By wife
Common Stock											529,798	I	See Footnote ⁽⁶⁾
		Table	II - Derivative (e.g., puts	e Securities A s, calls, warrar	cquire	ed, D ptior	isposed ons, convei	of, or l	Beneficial securities	lly C)wned		

Explanation of Responses:

Conversion

or Exercise

Price of

Security

Derivative

3. Transaction

(Month/Day/Year)

3A. Deemed

Execution Date,

if any (Month/Day/Year)

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$16.81 to \$17.7912. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Exercisable

5. Number

Derivative

Securities Acquired (A) or Disposed

(Instr. 3, 4 and 5)

of (D)

(A) (D)

Transaction

Code (Instr.

٧ Code

6. Date Exercisable and

Expiration

Date

Expiration Date

(Month/Day/Year)

7. Title and

Amount of

Securities

Derivative

Title

Underlying

Security (Instr. 3 and 4)

Amount Number

Shares

8. Price of

Derivative

Security

(Instr. 5)

9. Number of

derivative

Securities

Following Reported

(Instr. 4)

Date

Owned

Beneficially

Transaction(s)

11. Nature

of Indirect

Beneficial

(Instr. 4)

Ownership

Direct (D)

or Indirect (I) (Instr. 4)

Form:

- 2. The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$17.82 to \$18.8125. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 3. The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$18.82 to \$19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote
- 4. The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$18.73 to \$19.00. The Reporting Person undertakes to provide upon
- request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 5. The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from \$18.98 to \$19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 6. Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except

to the extent of his pecuniary interest therein, if any

Remarks:

1. Title of

Derivative

Security (Instr. 3)

/s/ Matthew Bartholomae.

12/23/2024 Attorney-in-Fact for Timothy

A. Springer

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.